Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix

Capnography Monitoring Solution Increases Patient Safety

By HospiMedica International staff writers
Posted on 31 Oct 2013
Print article
Image: The Capnostream 20p bedside monitor (Photo courtesy of Covidien).
Image: The Capnostream 20p bedside monitor (Photo courtesy of Covidien).
A new capnography solution offers enhanced features that could help clinicians identify and address serious respiratory care threats sooner.

The Capnostream 20p bedside monitor features the proprietary Apnea-Sat Alert algorithm, an algorithm that measures and reports recurring apnea and oxygen desaturation events, displaying the values directly on the Capnostream 20p monitor screen without requiring additional equipment or clinical workflow changes. Apnea-Sat Alert technology is also part of the broader family of Smart Alarm Management integrated algorithms that help to mitigate alarm fatigue, including Smart Breath Detection, a filter and pattern recognition algorithm that screens out low-amplitude “non-breath” etCO2 excursions like snoring, talking or crying, to provide a more accurate respiratory rate.

Other integrated algorithms include Smart Alarm for Respiratory Analysis (SARA), an alarm management technology that helps prevent alarm fatigue by reducing clinically insignificant respiratory alarms; Nellcor SatSeconds, a technology that helps analyze oxygen desaturation events; and the Integrated Pulmonary Index (IPI) algorithm that combines four respiratory measurements—capnography, respiratory rate, pulse rate, and pulse oximetry—to provide clinicians with an integrated snapshot of respiratory status.

The Capnostream 20p bedside monitor also includes the Microstream-enabled microMediCO2 module measurement bench, a module that offers easy integration into host monitor configurations, and is designed to support future Smart Capnography algorithms without requiring hardware upgrades. The Capnostream 20p bedside monitor is a product of Covidien (Dublin, Ireland), and has been approved by the US Food and drug Administration (FDA).

“Studies show that as many as 88% of hospitalized patients may be at risk for recurrent apneas, yet we’re only identifying and treating a very small number,” said Scott Kelley, MD, chief medical officer of respiratory and monitoring solutions at Covidien. “The Capnostream 20p bedside monitor will help increase apnea detection rates and represents an important advancement in continuous patient monitoring that we believe will help save lives.”

Related Links:

Covidien



Print article
Armstrong Medical Industries
Fluke Biomedical

Channels

Business

view channel

Global Advanced Patient Monitoring Market Worth USD 35.2 Billion in 2016

The global advanced patient monitoring market is worth USD 35.2 billion in 2016 and is being driven by the demand to integrate data processing capabilities and electronic medical records (EMR) transfer options, coupled with the increasing trend to upgrade to ambulatory and hand-held devices. These are the latest findings... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.